Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 822 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Cancer in My Community: The Role of Cancer Screening in Guatemala November 5, 2020 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma October 20, 2020 Targeted prostate cancer screening: Are we there yet? October 20, 2021 Load more HOT NEWS Online Dating During COVID-19 and Cancer: What to Know COVID-19 May Have Saved a Woman’s Life by Helping Her Discover... Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma
